Lancet 394:131138 Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB et al (2018) Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Exenatide-induced chronic damage of pancreatic tissue in rats
Bundle includes 3 months of medication, shipping, consultation, and injection kit
As depicted in Fig
Dose Escalation After four weeks at 1.5mg, the dose increases to 4mg for the next four weeks, then 9mg , before reaching the maintenance dose of 25mg daily